drugset / Trial / NCT06449859
A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects
Phase 1
Unknown
84 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is designed in two phases: single-dose administration and multiple-dose administration. A randomized, double-blind, placebo-controlled trial design was used to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of TQC2938 injection in healthy adults.
Timeline
- Start
- 2023-06-13
- Primary completion
- 2024-11
- Completion
- 2024-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQC2938 | Monoclonal antibody | 52.5 mg | Subcutaneous |
| Subject | TQC2938 | Monoclonal antibody | 210 mg | Subcutaneous |
| Subject | TQC2938 | Monoclonal antibody | 420 mg | Subcutaneous |
| Subject | TQC2938 | Monoclonal antibody | 630 mg | Subcutaneous |
| Subject | TQC2938 | Monoclonal antibody | 840 mg | Subcutaneous |
| Subject | TQC2938 | Monoclonal antibody | 1260 mg | Subcutaneous |